Flltr alrls with Turner' s Ivndromc 1671-4% 331 otller karvstvoesl aged 3 0 -9 9 Years treated with biosynthetlc 01 at dose o i 20 or 40 lU/, body suri ace per week In I :utcutaneou<~njectians. ' The patients wer e assi gned into 25 pairs accordi ng to the~r chronolo~ical age ICA), degree 01 bone retardation lBAl as coqared ulth their chronological age. average parelltal heliht and degree 01 growth deitciency 01 t he ch~ld In tens 01 man parental he~ght. In each patr, doses 01 20 lUia / week I Grouo A1 or 40 lUln ./week IGrou~ 8) upre randoml y assi gned.
We dld not ltnd signtiicant d!llerences among t he children in Gr oup I and B ~n t he younger age category.le did not find any d~iierences bet ween Groups A and B in bone age advai i ceaent over t he I year peri od 01 treatwnt regardl ess 01 the patlent's age We al so di d not observe any side-eiiects duri ng treatlent or d~lierences in lasting gl ucare or Insulin levels al ong Gr oups A and B l o believe that doses o i 611 exceed~ng 20 IUIm, body surl ace per week shoul d not be adn~ntstered to IS patients under the age or 7 years.
Lillle informatiEn is'available bn t h; inbucncc of CT alone on lineitr crowlh in
Cr was <iscontinucd after 3 yrs at i t medi a: age 019.0 yrs (3.7-14.1). hcdfan ige at lait obscrvatton was 14.9 (4.2-24.5). Medun lnlcrval between ccssallon o f lhcrapy and last follow-up was 7.0 yrs 1 9 17 6) He1 h l was measured at regular intervals from did noris until last follow-up. &dian'hiighl:%DS (YSDS) [or chronological age was calc$a&l. Scruni IGF-l and IGFBP-3 ;ire >tiltlul;8lcd hy lltc illcrc;isc o l pulr;ililc GI1 sccrciion ;ind G H lcvcls during pubcrly wit11 ;I sub\cquc~~t LiII in ;~d u l l h~x~d In childrcn wilh chronic rcniil litilurc, cllanpcb in tllc IGF-IIIGI'D1'-3 ritlio corrc1;llcd lo lhcir growlh rctiirdation. However, the indivtduitl IGF-IIICiI:IlP-3 ratio 11;i s nal previously bccrt described in hcalthy children durtnp puhclty and in p.ilicnls will1 ccnlr;il prccocious puherly (CPP). Muleriuls und melh~ds: 926 hc;ilthy children (0-20 ycitrb) and 23 girls with CPP (2-9 years) bclbrc and ;!flcr 2 yearb (11 1rc:ltrnenl wtlh G n R l l ;~n;~loguc and cyprolcrone acclalc participalcd. Scrum IGP-I .tnd IGFDP-3 wcrc an;llyzcd with spccilic RIA'S. Results: I n hcnllhv children scrum IGP-I and IGFBP-3 increased signilican~ly wilh age and pubertal ntilturation. When sgc and puhcrty wits lakcn into account, no signilic;tnt sex dil'fcrencc was dclcclohlc. The IGF-IIIGFBP-3 r;,lio incrc;~scd wilh age and pubcrly lrom a prcpubcrli~l mcitn (+/-SD) o l O.l K,5 (+/-0.025) to a m;lximum o l 0.107 (+I-0.022) (p<O.O(XlI) In Tanner sl;~gc IV. Cu~np;ircd 10 hc;lhlty childrcn of lhc wmc age, girls with CPP hind ;III incrcitrcd IGI:-IIUP-3 rslio oI'0.0% (+/-0.026). Aflcr 1rc:tlmcnl IGF-IIIGFBP-3 ratio Sl;tnd.~rd Dcvi.tlinn Scorc (SDS) (or CA decreased signilicitnlly, bul did no1 norrn;tlllc. +O. ' J uner +1.9 +0.3 t1.8 -0.01 Cunclusion:Thc IGF-IIIGPUP-3 r;llio incrc;trcs in norm;ll ;~nd precocious puberty cona1rnit;tnl with increased growlh vclocity.Gonnd:~l bupprcssion in CPP rcduccd height velocity which w;is rcflcclcd by ;t dccrc;lse in the IGF-IllGFBP-3 r;~lio.'ITtus, we suggest 111:i l lhc individual IGF-IIIGFUI'3 r:tlii) m;ly be an inilcx ~)fbiologicillly iiclivc frcc IGF-I. In A~I c h tlie anlod~lt 01 141 sou la1 free sndss s calic~laled uy Incasdrlng the resistance of the body to an electr~c current. The aim of the present study was to determ~ne the changes in body composition during childhood and puberty in normal Danish schoolchildren using tllc b~oelectrical impedance method. We examined bioelectrical impedance 1Holtain BCA. UKl, height, welght and pubertal stage (Tanner) in 388 chtldren. aged 6 to 1 6 years. titrls 2 7 3 6 8 31 1 3 2 5 3 10 In girls, we found a significant increase in body fat percent 1BF%) with age and pubertal maturatton (p<O.Ol ). In boys, there was no significant change with age or pubertal maturation, although there seemed to be a fall in BF% at the end of puberty (Tanner stages 4 & 5). There was no elfact of age on BF% w~t h i n the pubertal stages. There was for all age groups and pubertal stages a s~gn~ficant dlfference between g~rls and boys, w~t h the g~rls having the h~ghest values. FFM showed reciorocal values. The d~fferences accord~no to sex and aae found in this stu- Cystinosis is charactertzed by intracellular accumulation of cysttne, which causes nephropathy and severe growth retardation. We report on t w o prepubertal patients, adequately treated with oral adtn~n~stratiotr of cystalnine. We performed a 24 hour growth hormone (GHI prof~le and measured serum IGF-1 and urinary GH. One patient ( # I 1 was subsequently placed on GH therapy 12 ~Uim'lday).
PI. #1
Pt. n2 - 7.0 7.7 We found very high levels of urinary GH and low valucs of IGF-I. The 24h GH prof~les showed a normal number of peaks and values of mean concentration and AUC, which were low compared to those of norrnal prepubertal ch~ldren. We suggest that the growth retardation seen In cystinosis could be partly due to the excessive loss of GH in the urine, arnountlng to nearly 15% of the dally production and urinary filtration of GH. T h~s loss may contr~buti: to the low AUC,of the GH profiles. Treatment w~t h GH increases growth vclocity but thc effect on final S39 height is yet to be determ~ned.
